Jeffrey S Stonebraker

Case Article—Bayer New Drug Development Decision Making

INFORMS Transactions on Education.

Case—Bayer New Drug Development Decision Making

INFORMS Transactions on Education.

Reported prevalence of von Willebrand disease worldwide in relation to income classification

Haemophilia.

Converting factor and nonfactor usage into a single metric to facilitate benchmarking the resources consumed for haemophilia care across jurisdictions and over time

Stonebraker, J. S., O'Mahony, B., Noone, D., & Iorio, A. (2021, June 17). HAEMOPHILIA, Vol. 6.

Evaluation of the sexual health in people living with hemophilia

Germini, F., Chai-Adisaksopha, C., Pete, D., Curtis, R., Frick, N., Nichol, M. B., … Iorio, A. (2021, September 19). HAEMOPHILIA, Vol. 9.

Modelling future usage and cost of factor and emicizumab to treat haemophilia A for the US Western States Region IX haemophilia treatment centres

Haemophilia, 27(1).

Non‐severe haemophilia: Is it benign? – Insights from the PROBE study

Haemophilia, 9.

Risk Analysis, Practice, and Considerations in Capital Budgeting: Evidence from the Field for the Bio-based Industry

BIORESOURCES, 16(1), 19–45.

The World Federation of Hemophilia Annual Global Survey 1999‐2018

Haemophilia, 26(4), 591–600.

Establishing the Prevalence and Prevalence at Birth of Hemophilia in Males A Meta-analytic Approach Using National Registries

ANNALS OF INTERNAL MEDICINE, 171(8), 540-+.

Exploring regional variations in the cross-cultural, international implementation of the Patient Reported Outcomes Burdens and Experience (PROBE) study

HAEMOPHILIA, 25(3), 365–372.

Test-retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains

HAEMOPHILIA, 25(1), 75–83.

Latent therapeutic demand model for the immunoglobulin replacement therapy of primary immune deficiency disorders in the USA

Vox Sanguinis, 4.

Occurrence and impact of pain among patients living with hemophilia: An analysis from the patient reported outcomes, burdens and experiences (PROBE) study

Haemophilia, 24(S1), 26–27.

Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire

BMJ OPEN, 8(8).

The Effect of Inhibitors on Quality of Life and Pain in Adult Patients with Severe Haemophilia in the PROBE Cohort

Research and Practice in Thrombosis Haemostasis, 2(S1), 76–77.

The PROBE Data Dashboard - A new tool for real-time data visualization and analysis of patient reported outcomes

Haemophilia, 24, 181–182.

The PROBE Study –Global burden of bleeding from the mouth in Haemophilia – a call to action

Haemophilia, 24(S5), 66.

The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia

Pilot and Feasibility Studies, 4(1), 118–119.

Burden of Comorbid Diseases in Patients with Hemophilia: The Cross-Sectional Analysis of the Patient Reported Outcomes, Burden and Experiences (PROBE) Study

Blood, 130(S1), 3411.

Burden of comorbidities in persons living with haemophilia: insight from the PROBE phase 2b study database

Research and Practice in Thrombosis Haemostasis, 1(S1), 840–841.

Estimating the global annual bleed rate in haemophilia

Haemophilia, 23, 86–86.

Psychometric Properties of the Patient Reported Outcomes Burdens and Experiences (PROBE) Questionnaire

Blood, 130(S1), 5645.

Sexual Health in Patients with Hemophilia; The Insights from the Patient Reported Outcomes, Burdens and Experiences (PROBE) Study

Blood, 130(S1), 2141.

Test-retest reliability analysis of the Patient Reported Outcomes Burdens and Experiences (PROBE) study

Haemophilia, 23(S2), 50–51.

Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data

Haemophilia, 23(1), e1–e7.

Psychometric Test-Retest Reliability Analysis of the Patient Reported Outcomes Burdens and Experiences (PROBE)

Blood, 128(22), 5964.

The Patient Reported Outcomes, Burdens, and Experiences (PROBE) Phase 1

HTAi 2016 Annual Meeting Abstract Book, 63–64.

The Patient Reported Outcomes, Burdens, and Experiences (PROBE) Phase 1 Study Methodology and Feasibility

Haemophilia, 22(S2), 43–44.

The patient reported outcome burdens and experiences (PROBE) study - phase 1 results show PROBE study methodology feasible

Journal of Thrombosis and Haemostasis, 14(S1), 47.

How to measure progress in the provision of care for hemophilia

The Proceedings of the World Federation of Hemophilia’s Ninth Global Forum on Research and Treatment Products for Bleeding Disorders, 16–17.

Modeling Primary Immunodeficiency Disease Epidemiology and Its Treatment to Estimate Latent Therapeutic Demand for Immunoglobulin

JOURNAL OF CLINICAL IMMUNOLOGY, 34(2), 233–244.

A decision analysis model to estimate latent therapeutic demand for immunoglobulin therapy in primary immunodeficiencies

Proceedings of the 15th Meeting of the European Society Immunodeficiencies (ESID), 29–34.

Product-Generation Transition Decision Making for Bayer's Hemophilia Drugs: Global Capacity Expansion Under Uncertainty with Supply-Demand Imbalances

OPERATIONS RESEARCH, 61(5), 1119–1133.

A study of variations in the reported haemophilia B prevalence around the world

HAEMOPHILIA, 18(3), e91–e94.

Decision analysis model for estimating latent therapeutic demand for immunoglobulin therapy in primary immune deficiencies

Journal of Clinical Immunology, 32(S1), 18.

Impact factor as a metric to assess journals where OM research is published

JOURNAL OF OPERATIONS MANAGEMENT, 30(1-2), 24–43.

A study of reported factor IX use around the world

HAEMOPHILIA, 17(3), 446–455.

Empirically Investigating the Portfolio Management Process: Findings from a Large Pharmaceutical Company

In Portfolio Decision Analysis (pp. 131–148).

NC State's Supply Chain Resource Cooperative Educates in the Real World

INTERFACES, 41(6), 548–563.

Practice Summaries: American Airlines Uses Should-Cost Modeling to Assess the Uncertainty of Bids for Its Full-Truckload Shipment Routes

INTERFACES, 41(2), 194–196.

A study of reported factor VIII use around the world

HAEMOPHILIA, 16(1), 33–46.

A study of variations in the reported haemophilia A prevalence around the world

HAEMOPHILIA, 16(1), 20–32.

Factor Usage - Global Data.

The Proceedings of the World Federation of Hemophilia’s Sixth Global Forum on the Safety and Supply of Hemophilia Treatment Products for Bleeding Disorders – Making the Case for Clotting Factor Concentrates, 9–11.

OR Practice—Modeling Potential Demand for Supply-Constrained Drugs: A New Hemophilia Drug at Bayer Biological Products

Operations Research, 57(1), 19–31.

Balancing Environmental and Operational Objectives in Nuclear Refueling Strategies

In W. Edwards, R. F. Miles Jr, & D. von Winterfeldt (Eds.), Advances in Decision Analysis (pp. 564–581).

Understanding the supply-demand-price conundrum in the FVIII market

The Proceedings of the World Federation of Hemophilia’s Fifth Global Forum on the Safety and Supply of Hemophilia Treatment Products, 20–21.

Modelling haemophilia epidemiology and treatment modalities to estimate the unconstrained factor VIII demand

Haemophilia, 10(1), 18–26.

A country-by-country comparison of FVIII concentrate consumption and economic capacity for the global haemophilia community

Haemophilia, 9(3), 245–250.

Probabilistic Modelling of population-based epidemiology and treatment modalities to determine unconstrained factor VIII demand

Journal of Thrombosis and Haemostasis, 1(S1), P1645.

How Bayer Makes Decisions to Develop New Drugs

Interfaces, 32(6), 77–90.

New York Power Authority Uses Decision Analysis to Schedule Refueling of Its Indian Point 3 Nuclear Power Plant

Interfaces, 31(5), 121–135.

Formulating and solving sequential decision analysis models with continuous variables

IEEE Transactions on Engineering Management, 44(1), 43–53.

Practice Abstract: Decision Analysis Provides Insight to Ford Microelectronics Incorporated

Interfaces, 27(2), 107–111.

It’s Time to Think About Values First

Quality Air Force in the 21st Century: Technology & Innovation 1996 Quality Air Force Symposium Proceedings, 78–88. Maxwell Air Force Base, AL: Air Force Quality Institute.

Can source selection benefit from decision analysis?

Acquisition Research Symposium Proceedings, 287–298.

Simon says: Rational decision-making for source selection

Program Manager: Journal of the Defense Systems Management College, 20(5), 34–40.